Rybelsus vs Mounjaro: why this comparison needs a licence check first

The biggest misconception: Rybelsus is not a weight-loss medicine in the UK

Type most searches into a comparison engine and you will find Rybelsus described as though it sits alongside Mounjaro on a weight-loss shelf. It does not. The MHRA licenses Rybelsus (semaglutide 3mg, 7mg and 14mg tablets) for type 2 diabetes management in adults. Full stop. Using it off-label for weight loss falls outside that licence, and no UK prescriber should issue it for that purpose through a legitimate service.

This matters because the conversation shifts entirely when the comparison is reframed correctly. The oral semaglutide tablet that is licensed for weight management in the UK is Wegovy tablets, a different product, different strengths (1.5mg rising to 25mg), approved by the MHRA on 11 June 2026. If oral semaglutide for weight loss is what you are actually asking about, the weight-loss treatment overview covers both injectable and tablet options that hold the right UK licence.

Mounjaro, on the other hand, holds a full UK weight-management licence. It is a dual GIP and GLP-1 receptor agonist made by Eli Lilly, the only weight-loss medicine in the UK that works across two gut-hormone pathways simultaneously. If you are weighing up how it compares with semaglutide-based options, the Mounjaro versus Ozempic page is a useful place to understand how these medicines differ before looking at cost. The cost comparison between tirzepatide and semaglutide is a separate, relevant question once you have established you are comparing medicines that are each licensed for the same purpose.

What the trial numbers actually show, and why the Rybelsus figures belong in the diabetes column

Published trials for Rybelsus measured blood-sugar control and cardiovascular outcomes in people with type 2 diabetes, not weight loss as a primary endpoint. Weight reduction was observed as a secondary finding, but those numbers were generated in a diabetes population, at diabetes doses, chasing diabetes outcomes. Quoting them as weight-loss efficacy data misreads the trial design.

For Mounjaro in weight management, the picture is clearer. In the SURMOUNT-1 trial (2,539 adults with obesity but without type 2 diabetes, running 72 weeks) participants at the 15mg dose lost an average of around 20–21% of body weight, as published in the New England Journal of Medicine. The SURMOUNT-5 trial then compared tirzepatide head-to-head with semaglutide 2.4mg (injectable Wegovy) and found tirzepatide produced greater average weight reduction over 72 weeks. These are the relevant numbers for a weight-management comparison.

For anyone researching whether semaglutide or tirzepatide suits them better, the question of individual response is worth reading, because average trial results and individual clinical outcomes are different things.

What is actually licensed for weight loss, and what the Mounjaro vs Rybelsus search is often really asking

If you have landed here comparing the two, the genuine clinical question is probably one of these: Is there an oral weight-loss medicine? or How does Mounjaro compare with semaglutide-based options? Both have real answers.

On the oral question: yes, as of summer 2026 there is now a licensed oral option in the UK, Wegovy tablets (semaglutide 25mg maintenance). On the injectable semaglutide question, both Wegovy versus Mounjaro and the broader semaglutide versus Mounjaro pages go through the evidence properly. Neither routes through Rybelsus, because Rybelsus sits in the diabetes lane.

The table below sets out the key differences factually.

Source: NHS tirzepatide medicine guide; NICE TA1026.

Which medicine a prescriber might consider, and how the consultation works

Because Rybelsus falls outside the weight-management licence, a prescriber at a legitimate UK pharmacy would not prescribe it for that purpose. The licensed options are Mounjaro (injection), Wegovy (injection), or Wegovy tablets, each with its own eligibility criteria, trial profile and clinical fit. NICE recommends tirzepatide under TA1026 for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower thresholds applying for some ethnic backgrounds under UK guidance.

At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, not a triage algorithm. They look at your full picture: BMI, medical history, current medicines, and what you are trying to achieve. If approved, your Mounjaro KwikPen is dispatched the same day (for orders in before 12pm), and DPD delivers it to your door the next working day. The pen arrives in a plain box with no branding on the outside. That is a concrete detail worth knowing if discretion matters to you.

For a fuller side-by-side on the two licensed injectables, the Mounjaro versus Wegovy comparison is the place to go. Which of the licensed options suits you is a clinical decision our prescribers make with you. Speak to our prescribers and start your free consultation.